Johnson & Johnson reported a total revenue of $24.1 billion for the fiscal first quarter ended March 29, 2026, marking a 9.9% increase from $21.9 billion in the same period last year. The growth was driven by a 6.4% operational increase and a 3.5% positive impact from currency fluctuations. The company's net earnings for the quarter were $5.2 billion, translating to a diluted earnings per share of $2.14, a significant decrease from $4.54 per share in the prior year, primarily due to a one-time reversal of a $7 billion talc reserve in the previous fiscal period.
In terms of segment performance, the Innovative Medicine division generated $15.4 billion in sales, up 11.2% year-over-year, while the MedTech segment saw a 7.7% increase, reaching $8.6 billion. The Innovative Medicine segment benefited from strong sales in oncology products, particularly DARZALEX and CARVYKTI, which saw increases of 22.5% and 62.1%, respectively. However, the segment faced challenges with STELARA, which experienced a decline due to biosimilar competition. The MedTech segment's growth was bolstered by strong performance in cardiovascular and surgical products, although it was partially offset by competitive pressures in certain areas.
The company also reported significant operational changes, including the ongoing restructuring of its Orthopaedics business, which is expected to be completed by the end of fiscal 2026. This restructuring is part of a broader strategy to streamline operations and focus on core product lines. Additionally, Johnson & Johnson completed the acquisition of Intra-Cellular Therapies in April 2025, enhancing its portfolio in mental health therapeutics.
As of March 29, 2026, Johnson & Johnson had total assets of $200.9 billion, with cash and cash equivalents amounting to $21.7 billion, an increase from $19.7 billion at the end of the previous fiscal year. The company’s total debt stood at $55 billion, reflecting a net debt position of $32.9 billion. Looking ahead, Johnson & Johnson anticipates continued growth driven by its diverse product portfolio and strategic initiatives, although it remains cautious about the impact of market conditions and competitive pressures on its earnings.
About JOHNSON & JOHNSON
Johnson & Johnson is a global healthcare company focused on human health and well-being. It develops, manufactures, and sells pharmaceuticals, medical devices, and consumer health products across various segments including Innovative Medicine and MedTech. Serving markets worldwide, it offers key products in immunology, oncology, cardiology, orthopedics, and vision, leveraging innovation, strong intellectual property, and a broad distribution network to maintain a competitive edge.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.